Skip to content Synchronizing The Axis
Retatrutide: GIP/GLP-1/Glucagon Receptor Tri-Agonist
Retatrutide for Weight Loss
Retatrutide for weight loss represents a significant advancement in the realm of obesity management, emerging as a promising therapeutic option that harnesses the synergistic effects of multiple metabolic pathways. This novel drug functions by mimicking natural hormones involved in regulating appetite and energy expenditure, leading to enhanced satiety and reduced food intake. Furthermore, its unique formulation targets specific receptors associated with both glucose metabolism and fat regulation, distinguishing it from traditional weight-loss medications that often come with limited efficacy or undesirable side effects.
How to Mix RETA 10mg:
#1. On a large insulin syringe you pull 100 units of bacteriostatic water. (or 1ml )
#2. Put the 100 units of water very gently in one vial of Retatrutide.
#3. Very gently swirl the Vial or gently roll it on your table or countertop.
#4. Let the vial sit for about 30 minutes so the powder can dissolve on its own.
#5. Check the mixed Vial by looking from the bottom to see if there is any powder left. Once you see only clear water it’s ready to use.
PHOTOS
PRODUCT PHOTOS
How to use Retatrutide 10mg:
#1. Using an insulin syringe pull the mix and stop at 15 units. Once per week for week 1 and week 2.
#2. For week 3 and week 4 do the same but stop at 20 units.
#3. For week 5 and week 6 do the same but stop at 25 units.
#4. Continue the same way by increasing with 5 units every 2 weeks.
15, 15, 20, 20, 25, 25, ..
Why Retatrutide?
Unlike traditional diet pills or over-the-counter supplements that often focus solely on appetite suppression, Retatrutide utilizes a unique approach by mimicking the body’s natural hormones responsible for regulating metabolism and satiety. This dual-action strategy not only helps in reducing hunger signals but also enhances glucose control, making it a compelling choice for individuals struggling with obesity or those affected by metabolic conditions such as type 2 diabetes.
Triple-Action & Science Focus
- Three pathways. One goal.
- The power of three, perfected.
- Activating the triple-agonist advantage.
- Redefining metabolic science.
- Beyond dual action: The triple G effect.
Metabolism & Energy
- Unlock your metabolic potential.
- Spark your burn from within.
- Turn on the heat, turn off the hunger.
- Energy released, weight released.
- Reset your body’s baseline.
Transformation & Progress
- The next wave of wellness.
- Shaping a healthier tomorrow.
- Advanced science for deep transformation.
- Reach beyond your limits.
- Rewriting the rules of weight loss.
Frequently Asked Questions
Yes. A nested trial studied participants with knee osteoarthritis, and results pointed to reduced knee pain alongside weight loss, likely tied to less joint strain and lower inflammation
Yes. Another nested trial included participants with moderate to severe obstructive sleep apnea, and the drug showed improvement in that condition too consistent with how significant weight loss often eases sleep apnea severity.
Yes. Retatrutide showed significant improvements in glycaemic control and bodyweight reduction as a monotherapy in adults with type 2 diabetes that is inadequately controlled with diet and exercise alone
Yes. Significant improvements were observed in blood pressure, lipid (cholesterol) profiles, and liver fat content among trial participants.
One expert who has consulted for Eli Lilly described retatrutide as the GLP-1-class medicine viewed as the most potent, with the greatest weight loss potential, since it acts on an extra hormone pathway that those drugs don’t target. That said, no direct head-to-head trial has compared them yet.
Trial results have been described as historic. Participants using the highest doses achieved weight loss described as putting retatrutide essentially on par with bariatric surgery for some participants who tolerated dose escalation to the maximum level.
No. Eli Lilly is expected to submit its FDA application later in 2026, with approval potentially following in 2027 and commercial availability after that. It isn’t a legally available, approved prescription drug today.
This is one of its most promising benefits. The glucagon receptor component is believed to help the liver burn stored fat more effectively, a mechanism not present in GLP-1-only or dual GIP/GLP-1 drugs like semaglutide and tirzepatide. Trials have shown meaningful improvement in liver fat content, which matters for conditions like MASLD (fatty liver disease)
The trial reported an adverse event profile consistent with other drugs in its class, meaning GI-related side effects (nausea, vomiting, diarrhea) similar to other GLP-1 drugs are expected. Longer-term safety data are still being collected as more trials report through 2026.
It’s an investigational injectable medication known as a “triple agonist” — it targets three hormone receptors (GLP-1, GIP, and glucagon) instead of just one or two, unlike earlier drugs such as semaglutide (Wegovy) or tirzepatide (Zepbound). It’s developed by Eli Lilly and is not yet approved by the FDA — it remains investigational.
